Table S1. Clinical characteristics of patients with carbapenem-resistant *Acinetobacter calcoaceticus-baumannii* complex who died or survived by end of study in the cefiderocol arm in the CREDIBLE-CR study

	Patients with CRAB infection treated with cefiderocol in the CREDIBLE-CR study (N=38)	
Parameters at randomization	**Patients who died by EOS n=19**	**Patients who survived by EOS n=19**
Age		
Mean (SD)	64.0 (17.1)	54.5 (23.8)
Median (range [min–max])	69 (24–86)	67 (23–91)
Sex		
Male, n (%)	11 (57.8)	13 (68.4)
Female, n (%)	8 (42.2)	6 (31.6)
ICU, n (%)	16 (84.2)	16 (84.2)
Mechanical ventilation, n (%)	15 (78.9)	12 (63.2)
APACHE II		
Mean (SD)	18.6 (5.6)	15.1 (6.0)
Median (range [min–max])	18 (12–29)	15 (5–26)
SOFA		
Mean (SD)	7.7 (3.9)	5.3 (3.4)
Median (range [min–max])	7 (3–17)	4 (1–12)
CCI		
Mean (SD)	7.0 (2.5)	3.4 (2.3)
Median (range [min–max])	7 (3–11)	4 (0–7)
Severe/moderate renal impairment,* n (%)	9 (47.4)	3 (15.8)
Any organ failure, n (%)**	15 (78.9)	7 (36.8)
Ongoing or prior (within 31 days) septic shock	8 (42.1)	1 (5.3)
Sepsis without septic shock	2 (10.5)	0 (0)

APACHE II, Acute Physiology And Chronic Health Evaluation II; CCI, Charlson Comorbidity Index; CRAB, carbapenem-resistant *Acinetobacter calcoaceticus-baumannii* complex; EOS, end of study; ICU, intensive care unit; SD, standard deviation; SOFA, Sequential Organ Failure Assessment.

*Based on creatinine clearance [1].
**Includes any acute or chronic renal, lung, liver, and/or cardiac failure or insufficiency reported in medical history prior to randomization.

Reference

1. Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, Lodise TP, Naas T, Niki Y, Paterson DL, Portsmouth S, Torre-Cisneros J, Toyoizumi K, Wunderink RG, Nagata TD. 2021. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 21:226–240.